about
Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophagesKinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaquesHuman recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.IgG subclass and heavy chain domains contribute to binding and protection by mAbs to the poly γ-D-glutamic acid capsular antigen of Bacillus anthracis.Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsuleBiosensing with nanofluidic diodes.Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway.Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans.Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide.Identification of Burkholderia cepacia complex bacteria with a lipopolysaccharide-specific monoclonal antibody.Activation of the alternative complement pathway by fungal melaninsThe capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyAntibody interactions with the capsule of Cryptococcus neoformansCapsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodiesInterdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans.Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast.Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages.Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide.Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformansFc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificityModulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans.The road to toxin-targeted therapeutic antibodies.Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei.Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophagesMolecular architecture of the Cryptococcus neoformans capsule.Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsivenessNon-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharidePhagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophagesImmune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibodyImmunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosisDifferential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.Fungal diagnostics.Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen
P50
Q28297961-2c9b86ed-42d8-cae7-314c-2e56df02f77fQ28389893-6f8f55ea-4602-7aa3-75d9-68240ead55a5Q30804794-e7c7d8c1-46ba-65c5-680f-9505a9da04fdQ31116360-404b2217-4392-8d1f-38bf-d781f79c3d3eQ33261310-5aafbab2-4377-cdb5-c969-b85f41c9ba96Q33641004-1b390e07-4821-2c23-1f44-ae895a66c967Q33675896-94399da1-4347-3262-2bac-e22af545ef7eQ33693515-c6c61297-45af-2c1c-f6b4-fe1eb2fd197aQ33752377-71d6db74-4fcb-4972-e164-013171287cf1Q33762293-3c9e5e42-4061-fbee-0089-67ee5f905a55Q33765773-b8ef8ed0-4986-6b8c-5b47-f5a87e917bb5Q33770188-ec06b183-4bc9-7152-05e7-d7a24e6e4194Q33905575-212d9651-4454-fa40-56e0-37a576d67b6bQ33920487-23a9ed9e-466f-4c1c-0c95-7e0ab548fdd0Q33941268-4e22f744-4d55-48cb-a5c1-40dfd8ce3b6bQ34001769-ccfad22a-4ba3-f7bb-225f-c9d7a4bcfb9eQ34004832-67321ea7-48b3-8ca1-16db-e34e9f682cccQ34006122-bf6ed96e-4928-6ddf-0e8c-960959bdacfaQ34009212-8ee924fc-430a-ae10-9fa6-08f5483a913fQ34009739-b2396e3d-4a4d-7f6e-35b4-2e8fe0057e62Q34088603-20341cdb-44c5-ca16-73a5-1fd697b50cfeQ34088651-614362d1-4e81-44fb-21af-2b2ecde56a98Q34096432-74b99294-41bd-29f7-489c-cd6c0450b3f5Q34123230-be75a832-44af-f397-9d44-fdfeaf1de736Q34125581-f0c88186-485c-677d-4d30-776ecddc5f92Q34165426-40b12f3b-4630-ec8a-2d32-af8085c5d91bQ34166527-2a5bbacf-455c-815a-e17b-94f4d53965ffQ34243707-956b5309-48f2-f1f7-44c0-617113c6ccb6Q34301177-0d9629d3-4f40-de95-1193-694bc698794dQ34309345-0b8d6469-49be-a51d-8dbf-bb8aa35ddd52Q34420549-6307fc86-4ed2-9baf-202d-869afc74b3f4Q34429542-a54c415d-4d54-0bef-c196-0ed6ff80c859Q34454156-de4d0194-4a6c-d5ff-d020-ee867c19a8c0Q34466900-7868b9c6-4368-f110-f627-8b6cd555e1bcQ34492622-20c763fb-4730-8e21-46b8-f95fd11675b3Q34681238-e6e5340b-489f-ce85-29d3-e17c4e1bbc92Q34779166-3e4d4306-4897-ef36-88a4-663e0d1d2463Q35110746-9c6db43d-4aae-7daa-bbe4-fd8b784eb09bQ35137799-6a95c3e7-431f-2463-7a96-5c35032d29aeQ35138768-f3bf8d47-43bc-c057-934b-09e6378732e7
P50
description
academisch docent
@nl
microbiologist
@en
name
Thomas R. Kozel
@ast
Thomas R. Kozel
@en
Thomas R. Kozel
@es
Thomas R. Kozel
@nl
type
label
Thomas R. Kozel
@ast
Thomas R. Kozel
@en
Thomas R. Kozel
@es
Thomas R. Kozel
@nl
altLabel
Thomas Kozel
@en
Thomas R Kozel
@en
Tom Kozel
@en
prefLabel
Thomas R. Kozel
@ast
Thomas R. Kozel
@en
Thomas R. Kozel
@es
Thomas R. Kozel
@nl
P69
P1153
7007083036
P1960
_-C3s6kAAAAJ